Waldenström Macroglobulinemia: Ibrutinib for Rituximab-refractory Patients

Share this content:
Ibrutinib monotherapy resulted in sustained responses and a meaningful progression-free survival benefit among heavily pretreated patients.
Ibrutinib monotherapy resulted in sustained responses and a meaningful progression-free survival benefit among heavily pretreated patients.

Ibrutinib monotherapy resulted in sustained responses and a meaningful progression-free survival benefit among heavily pretreated patients with rituximab-refractory Waldenström macroglobulinemia, according to a study presented at the American Society of Hematology (ASH) 58th Annual Meeting and Exposition (also published in The Lancet Oncology.)1

Few treatment options exist for rituximab-refractory Waldenström macroglobulinemia. Researchers evaluated the efficacy and safety of ibrutinib in this patient setting.

For the substudy of an international, phase 3 trial (ClinicalTrials.gov Identifier: NCT02165397), researchers enrolled 31 patients with Waldenström macroglobulinemia whose disease relapsed less than 12 months since the last dose of rituximab or who failed to achieve at least a minor response to rituximab therapy. All participants received ibrutinib daily until disease progression or unacceptable toxicity.

After a median follow-up of 18.1 months, 90% of patients achieved an overall response, including 71% who had a major response.

The 18-month progression-free survival and overall survival rates were 86% (95% CI, 66-94) and 97% (95% CI, 79-100), respectively.

Investigators observed a median increase in hemoglobin levels of 1.1 g/dL after 4 weeks of ibrutinib therapy. The median hemoglobin level at week 49 was 12.7 g/dL.

RELATED: Ofatumumab Monotherapy Active in Waldenström Macroglobulinemia

The most frequently reported grade 3 or higher adverse events were neutropenia (13%), hypertension (10%), and anemia, thrombocytopenia, and diarrhea each in 6%. Nearly one-third of patients reported serious adverse events.

The findings suggest that single-agent ibrutinib is a new chemotherapy-free treatment strategy for heavily pretreated, rituximab-refractory Waldenström macroglobulinemia.

Reference

  1. Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2016 Dec 9. doi: 10.1016/S1470-2045(16)30632-5 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters